Cixutumumab-Associated Pancolitis in a Patient With Prostate Cancer

Mehmet Asim Bilen, Jeri Kim, Huamin Wang, Shi-Ming Tu
2013 Clinical Genitourinary Cancer  
Introduction New therapies for cancer have emerged as we have gained better understanding of the molecular mechanisms that underlie those diseases. Several types of tumors, including prostate cancer (PC), overexpress the insulin-like growth factor 1 receptor (IGF1R). 1 The antitumor effect of IGF1R inhibition has been noted in both in vitro and in vivo models of PC. 2,3 Several different agents, including such monoclonal antibodies as IMC-A12 (cixutumumab), have been developed as antagonists to
more » ... IGF1R. 4-6 Because of its antitumor activity in tumor cell models, cixutumumab has advanced into clinical studies. 7 Recent phase I and II studies in patients with various cancers showed that this agent is well tolerated and without unreasonable side effects. We describe here, to our best knowledge, the first case of a patient with PC who developed pancolitis while participating in a clinical trial of cixutumumab. Case Report A 53-year-old white man was seen by a local physician for musculoskeletal pain in the lower back and neck ultimately resulting in upper-extremity weakness. Further evaluation, including a prostate biopsy performed in March 2007, revealed Gleason score 9 (4+5) prostatic adenocarcinoma. At that time, his prostate-specific antigen (PSA) concentration was 953 ng/mL, a bone scan showed diffuse bony metastasis, and computed tomography (CT) scanning revealed retroperitoneal and pelvic lymphadenopathy.
doi:10.1016/j.clgc.2012.09.009 pmid:23083799 pmcid:PMC3579009 fatcat:2gvz656zhbacfdvu52xgfkmziu